◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: medium Compound SKIP-FOR-NOW HIGH

Nandrolone

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

For this user-archetype (20yo MMA athlete + business owner, peak endogenous T, brain-priority stack) — nandrolone is a SKIP across every dimension. (1) HPG-axis suppression is among the deepest of any AAS — single doses of 100-200 mg ND suppress LH/FSH for weeks; multi-month cycles produce HPG recovery times routinely measured in 6-18 months and well-documented permanent hypogonadism in young users; the long decanoate ester releases for 4-6 weeks after final injection so PCT must be timed to ester clearance. (2) The signature "Deca dick" mechanism — PR agonism → dopamine suppression → prolactin elevation → erectile dysfunction + libido crash — is exactly the OPPOSITE of what an MMA athlete training brain-body coordination needs; the biohacker workaround (cabergoline) introduces a serotonin-pathway dopamine agonist with valvulopathy risk and adds prescriber friction. (3) WADA S1.1a banned with the LONGEST detection window of any commonly-used AAS — 12-18 months in urine via 19-norandrosterone metabolite; precludes any pivot to sanctioned amateur or pro MMA competition for ~18 months post-cycle. (4) The "joint pain relief" thesis (Tatem 2020 pilot) is real but extrapolated from hypogonadal middle-aged men; in a 20yo with peak endogenous T, the marginal benefit over BPC-157 + collagen + load management is essentially zero while the harm profile is enormous. (5) Lipid profile (HDL crash, LDL/ApoB rise) and modest BP elevation are class-typical; nandrolone is on the milder end of the AAS lipid-disruption spectrum but still clinically meaningful at multi-month doses. (6) Recent 2026 Prokopidis meta-analysis of 20 RCTs found ND modestly increased lean soft tissue (+1.59 kg) but did NOT improve handgrip strength or consistently improve BMD — meaning even the strongest "earned" claim (mass gain) doesn't translate to functional strength in controlled trials. HIGH (not MEDIUM) confidence because the verdict converges across HPG/fertility (deep suppression at young age), sport regulation (WADA + 18mo detection), sexual function (the PR-mediated mechanism is unique and severe), and the user's specific brain-priority + athletic-tested-status profile. Would change to OPTIONAL-ADD only if the user is post-30, post-fertility-checkpoint, has documented hypogonadal joint pain refractory to BPC-157/load management, AND is competing in non-tested categories — none of which apply.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, MMA athlete (this user)
    SKIP-AT-

    HIGH confidence. Verdict converges across HPG/fertility (deep + long suppression), sport regulation (WADA + 18mo urine detection), sexual function (signature PR-mediated dysfunction), brain-priority (dopamine suppression mechanism conflicts with cognitive/mood baseline), achievable alternative for joint pain (BPC-157 + collagen + load management). Marginal benefit over alternatives is essentially zero; harm profile is enormous.

  • 30-50, executive maintenance, lifestyle-optimized, low-T documented
    NOT-INDICATED

    for general TRT — testosterone Rx via TRT clinic is the correct first-line tool. Nandrolone's role is as ADJUNCT to TRT for specific indications (joint pain, mass goals).

  • 30-50, hypogonadal + refractory joint pain, on TRT, fertility-checkpoint complete
    OPTIONAL-ADD

    as Tatem-protocol adjunct (100-200 mg ND every 2-3 weeks × 8-12 weeks) IF on TRT base, with prolactin monitoring + cabergoline available, and only if BPC-157 + collagen + ortho/PT have failed.

  • 30-50, recreational physique optimization, post-baseline-monitoring, tested-status
    —

    no: OPTIONAL-ADD as Tier-2 cycle component with all the standard caveats. Run with TRT base + cabergoline + AI + monitoring framework. Better-suited for "dry, lean" Tier-2 cycles than for mass cycles.

  • 50+, recovery / quality-of-life optimization
    NOT-INDICATED

    Polycythemia + cardiovascular risk grows with age. TRT (if indicated) at low-normal-restoration doses is a different conversation.

  • Anxiety-prone
    AVOID

    Nandrolone is generally less anxiogenic than tren but the PR-mediated mood/sexual/dopamine signature can produce flat-affect patterns that compound anxiety in vulnerable users.

  • High athletic load, tested status (combat sport, endurance, strength competing in WADA-tested events)
    HARD SKIP

    WADA S1.1a banned, 12-18 month urine detection window is among the longest of any AAS.

  • Sleep-disordered
    CAUTIOUS

    if sleep apnea present (RBC + BP + neck soft tissue can worsen).

  • Recovery-focused (post-injury, post-illness)
    NOT-INDICATED

    in young eugonadal users. [BPC-157](bpc-157.md), [TB-500](tb-500.md), [GHK-Cu](ghk-cu.md) are mechanism-aligned for tissue repair without HPG / sexual / cardiovascular cost.

  • Strength/anabolic-focused, post-30, fully baselined, NOT competing tested
    OPTIONAL-ADD

    as Tier-2 / Tier-3 in a well-monitored cycle architecture.

  • Anemia (renal or AIDS-wasting clinical context)
    PRIMARY-PICK

    historically; now obsolete — rhEPO is standard of care for renal anemia; antiretrovirals + nutrition for AIDS wasting.

  • Postmenopausal osteoporosis
    NOT-FIRST-LINE

    bisphosphonates, denosumab, romosozumab are evidence-based first-line. ND remains an option per Frisoli 2005 / Prokopidis 2026 in selected refractory cases.

▸ Subjective experience (deep)

Per biohacker community reports at typical bodybuilding doses (200-400 mg Deca/wk OR 100-200 mg NPP every 2-3 days):

  • Onset: Slow with Deca due to long ester (~3-4 days to peak after first injection, full steady-state takes 4-6 weeks). NPP onset noticeable in 1-2 weeks.
  • Mass progression: Slow, steady, "dry" lean mass accrual visible from weeks 3-4, peaking weeks 8-12. Less acute scale-weight jump than testosterone or dianabol. The Prokopidis meta's +1.59 kg LST represents the controlled-trial median, smaller than community-reported gains because of the placebo correction and study-population effect (often non-athletic).
  • Joint relief: Often reported within 4-6 weeks. Described as "feeling lubricated," "wet joints," "shoulders moving without pop." This is the most consistent non-mass benefit and drives much of the off-label sourcing.
  • Strength signal: Weaker than testosterone or trenbolone for raw strength. Aligns with Prokopidis 2026 finding of NO handgrip strength improvement in pooled RCTs.
  • Libido trajectory: Often elevated in first 2-4 weeks (typical AAS supraphysiologic phase), then degrades — sometimes to anorgasmia/ED — by weeks 4-8 in PR-sensitive users (the "Deca dick" emergence window). Cabergoline co-administration prevents this in many users; some users get it anyway.
  • Erection quality: Specifically affected — even when libido is preserved (mental drive intact), the physical erection may not happen ("can't get it up despite wanting to"). This is the prolactin-mediated central effect.
  • Mood: Mostly neutral to mildly calm. Distinct from testosterone (drive/aggression) and trenbolone (anxiety/insomnia). Some users report "flat" affect, possibly the dopamine-suppression mechanism.
  • Sleep: Variable — generally not the worst AAS for sleep, but some users report disruption at higher doses or with elevated hematocrit.
  • Discontinuation: Long taper-out for Deca — ester continues releasing for 4-6+ weeks after last injection. NPP clears in 2-3 weeks. HPG axis stays suppressed for the full taper plus recovery period (typically 4-12+ months for Deca, faster for NPP).
  • PCT timing: Critical — must wait ~6 weeks after last Deca injection for ester clearance before SERM-based PCT, otherwise SERMs are fighting active suppression.

Reality check. The "Deca dick" phenomenon is real, mechanistically grounded, and not avoidable purely with cabergoline in all users. The "wet joints" benefit is real but cheap-to-replicate with collagen + load management + (for the user specifically) BPC-157, which is mechanism-aligned for joint tissue without HPG/sexual cost.

▸ Tolerance + cycling deep dive
  • Tolerance: AAS-class shows mild AR-density downregulation with sustained use. Not the rate-limiting factor for cycle design.
  • Recommended cycle length: 12-16 weeks for Deca (long ester), 8-12 weeks for NPP. Many bodybuilders run longer; risk integrates.
  • TOE = TON heuristic (time off equal to time on): Common community rule. In practice, full HPG / lipid / sexual function recovery often takes longer than time-on for Deca specifically due to the long ester + deep PR-mediated suppression.
  • Cumulative cycle damage: Lipid changes, cardiac structural changes, HPG dysfunction integrate over years. The "blast and cruise" pattern (cycles + TRT-doses indefinitely) represents permanent commitment to exogenous T.
▸ Stacking deep dive

Synergistic with (for appropriate populations only — i.e., NOT this user-archetype at 20)

  • testosterone-cypionate / testosterone-enanthate: Standard "TRT base" companion to Deca/NPP. Almost always required because Deca's HPG suppression eliminates endogenous T and Deca alone produces sexual dysfunction even before "Deca dick" emerges.
  • anastrozole: Estrogen management adjunct; less critical than on T cycles (Deca aromatizes ~20%) but still useful especially with TRT base on top.
  • cabergoline: THE distinctive Deca-cycle adjunct. Dopamine D2 agonist; prevents/reverses "Deca dick" via prolactin suppression. 0.25-0.5 mg 2×/week. Many advanced users run prophylactically from week 1.
  • hcg (250-500 IU 2× weekly during cycle): Maintains testicular volume / responsiveness; used to ease PCT.
  • primobolan (methenolone enanthate): Common Tier-2 stack — both relatively mild AAS, both non-aromatizing or weakly aromatizing, both with reasonable lean-quality reputations. "Primo + Deca" is a classic "moderate" stack.
  • Collagen + Vitamin C: Mechanism-aligned for the joint-trophic effect Deca provides via type III collagen synthesis upregulation. Cheap, OTC, no side effects.

Avoid stacking with

  • finasteride / dutasteride: PARADOXICALLY WORSENS androgenic effects by blocking 5α-reduction of nandrolone to weaker DHN. The OPPOSITE of finasteride's effect on T-cycles. Documented in transfemscience writeup, MorePlatesMoreDates educational content. Use a topical anti-DHT approach (RU58841 — also not recommended) or accept the risk; do NOT add finasteride to a Deca cycle expecting it to help.
  • trenbolone: Stacking PR-active progestins (Deca + Tren are both 19-nor compounds with PR activity) compounds prolactin/dopamine signature severely. "Deca dick + Tren cough + Tren insomnia + anxiety" is among the worst sexual-function/mood combinations in AAS practice.
  • Other strong erythropoietic AAS (boldenone, high-dose testosterone): Compounds polycythemia risk.
  • 17α-alkylated orals (dianabol, anavar, winstrol): Hepatotoxicity stacking; cumulative liver burden.
  • NSAIDs (chronic): BP / kidney load stacking with the BP-elevating effect.
  • SSRIs / serotonergic agents: Some users report worsened sexual dysfunction with SSRI + Deca stack (compounded prolactin, compounded ED). Mechanistic basis is plausible.

Neutral / safe co-administration

  • Most CNS nootropics (modafinil, racetams, citicoline, magnesium) — no direct interaction
  • Vitamin D, omega-3, basic micronutrient stack — no interaction
  • BPC-157, TB-500 — no known interaction; if joint-pain relief is the goal, BPC-157 covers that without HPG/sexual cost
▸ Drug interactions deep dive
  • Finasteride / dutasteride: PARADOXICALLY WORSENS androgenic effects (see Stacking — Avoid).
  • Warfarin / DOACs: Theoretical interaction via lipid panel / hepatic CYP changes; AAS users on anticoagulation need monitoring.
  • Insulin / oral antidiabetics: AAS class generally improves insulin sensitivity at moderate doses; can worsen at high doses; monitor.
  • Antihypertensives: Often need uptitration on cycle.
  • CYP induction/inhibition: Nandrolone is metabolized by 17β-HSD and via 3α-/3β-HSD pathways; mild hepatic CYP3A4 modulation at high doses but not clinically dominant.
  • Levothyroxine / thyroid hormones: AAS may alter SHBG / free hormone fractions; recheck thyroid panel on cycle if symptomatic.
  • Cabergoline + dopaminergic antipsychotics: Counter-pharmacodynamic; not a stack anyone would do.
  • Cabergoline + ergot alkaloids / 5HT-2B agonists: Compounds valvulopathy theoretical risk.
  • Estrogen-containing products, oral contraceptives: Counter-pharmacodynamic for male users; some women on contraceptives containing norethisterone (a 19-nor progestin) can show false-positive 19-norandrosterone in WADA testing — context for the WADA threshold.
▸ Pharmacogenomics
  • AR (androgen receptor) CAG repeat length: Shorter CAG repeats → more sensitive AR → stronger response per mg AAS. Trackable on 23andMe via manual analysis.
  • CYP19A1 (aromatase) variants: Influence the residual aromatization rate; "high aromatizers" may need AI even on Deca despite the ~20% rate.
  • SRD5A2 (5α-reductase type 2) variants: Less impactful for nandrolone than for testosterone (because 5α-reduction deactivates nandrolone). Reduced 5α-reductase activity may increase nandrolone-driven androgenic side effects (mechanism mirrors finasteride paradox).
  • DRD2 / dopamine receptor variants: Theoretical relevance for "Deca dick" susceptibility — users with reduced D2 dopaminergic tone may be more prone to PR-mediated dopamine-suppression effects.
  • HFE / iron-metabolism variants: Compound polycythemia risk.
  • APOE / lipid-metabolism variants: APOE ε4 carriers may show worse lipid response.
  • Practical takeaway for this user: No actionable pharmacogenomics for prescribing decisions because the prescribing decision is "don't." 23andMe results (June 2026) will inform any future AAS conversation post-30.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (human) Brand Deca-Durabolin (Organon) — discontinued; Empower Pharmacy compounded ND $80-200 / 10 mL @ 200 mg/mL High (compounded) Empower Pharmacy is the dominant US 503A-compounded ND supplier as of 2026. Requires prescription; off-label use for hypogonadal joint pain is the most common Rx pathway.
US Rx (TRT clinic) Various men's health / hormone optimization clinics $150-400/mo as part of multi-drug protocol Variable Some clinics will Rx ND as adjunct to TRT for joint pain in selected hypogonadal patients (Tatem-style protocol). Most won't for under-30 with normal T.
Gray-market underground lab (UGL) Various — quality varies $40-100 / 10 mL @ 200-300 mg/mL Variable Most common path for human off-label use. Reputable UGLs publish HPLC + sterility testing (Janoshik, Anabolic Lab); many do not. ND is among the more frequently underdosed AAS in UGL testing because the long-chain ester takes vial mass.
International pharmaceutical-grade (Mexico, India, Eastern Europe) Various Variable Variable Crossing border with these is a controlled-substance felony under US federal law.
Veterinary product Limited; ND is not a major veterinary product like boldenone N/A N/A Not a meaningful sourcing path.

Quality concerns with gray-market:

  • ND is among the more commonly underdosed AAS in UGL testing (decanoate ester takes ~30% of vial mass — manufacturers sometimes cheat the nandrolone:ester ratio).
  • Bacterial contamination of injectable oil → abscesses, sepsis, sterile abscesses.
  • Carrier oil reactions (cottonseed > sesame > MCT) and post-injection pain (PIP) — NPP particularly aggravating.
  • Counterfeit "Deca-Durabolin" labeled as Organon when discontinued from US market.

Note for this user: Sourcing is solvable (compound pharmacy + Rx OR UGL path). The verdict isn't "can't get it" — it's "shouldn't take it at 20." The compound's PR-mediated mechanism, deepest-in-class HPG suppression, and 18-month urine detection window stack against any combat-sport athlete with brain-priority and tested-status uncertainty.

▸ Biomarkers to track (deep)

Baseline (before cycling, ideally 2-4 weeks of fasted-AM panels for stability)

  • Total testosterone, free testosterone, SHBG (LC-MS preferred)
  • Prolactin (CRITICAL for nandrolone — get baseline before any exposure)
  • Estradiol (sensitive assay, LC-MS or ECLIA)
  • LH, FSH
  • Hematocrit, hemoglobin, RBC count, MCV, ferritin
  • Lipid panel: LDL-C, HDL-C, ApoB, oxLDL (if available), Lp(a) (one-time genetic-set baseline)
  • ALT, AST, GGT, alkaline phosphatase
  • Comprehensive metabolic panel (creatinine, eGFR, electrolytes)
  • Blood pressure (24-hr ambulatory ideal; multiple manual readings minimum)
  • Resting heart rate, ECG baseline
  • PSA (>30yo)
  • IIEF-5 (International Index of Erectile Function — 5-item) baseline
  • Sperm analysis (if fertility-relevant)
  • Echocardiogram (>30yo or with prior cycles or family CV history)

During use (every 4 weeks on cycle)

  • Prolactin (every 4 weeks; threshold for cabergoline initiation: prolactin >ULN or any sexual function decline)
  • Hematocrit, hemoglobin (every 4 weeks; threshold: HCT >54%)
  • Lipid panel (every 8-12 weeks; expect HDL crash, LDL/ApoB rise)
  • Total / free T, E2 sensitive (every 6-8 weeks for AI titration)
  • LH, FSH (1× mid-cycle to confirm suppression — clinical interest only)
  • BP, resting HR (weekly self-tracking; clinical re-check every 4 weeks)
  • ALT, AST (every 6-8 weeks)
  • IIEF-5 / libido symptom log every 2 weeks (early warning for "Deca dick" emergence)
  • Symptom log: anxiety, sleep changes, mood, gyno surveillance, joint pain status

Post-cycle (PCT through recovery)

  • Prolactin every 4 weeks until normalized
  • Total / free T, LH, FSH every 4-6 weeks until recovered (6-18 months typical for Deca)
  • E2 sensitive (post-AI clearance can produce E2 rebound)
  • Lipid panel re-baseline at 12 weeks post
  • Hematocrit re-baseline at 8 weeks post
  • IIEF-5 every 4 weeks until recovered
  • Sperm analysis at 6-12 months post if fertility-relevant
  • BP, resting HR re-baseline at 4-8 weeks post
▸ Controversies / open debates Live debate

  1. The "milder than testosterone" claim. True for DHT-pathway tissues (scalp, prostate, skin). False or REVERSED for sexual function (PR-mediated "Deca dick" is more severe than T's typical AAS sexual signature). False for HPG suppression (Deca is among the deepest suppressors). The blanket "milder than T" claim oversimplifies; nandrolone is mild on some axes and worse on others.

  2. The finasteride paradox. Established mechanistically and reported anecdotally consistently — but no published RCT. Belongs in every nandrolone education resource because the standard intuition (finasteride helps with AAS-induced hair loss) is exactly wrong.

  3. "Deca dick" frequency and severity. Estimates range 20-50% in observational reports. Whether prophylactic cabergoline reliably prevents it in all users vs. a meaningful subset of resistant cases is debated. Some users with proper E2 + prolactin management still develop it.

  4. Functional strength vs. mass. Prokopidis 2026 meta found mass increase WITHOUT handgrip strength improvement in pooled RCTs. This is a meaningful negative finding — mass alone doesn't translate to function. Bodybuilding community framing of "Deca = real strength" may be overestimated; what users feel as "strength" is partly RBC-driven endurance and joint-comfort effects, not contractile force.

  5. Joint-pain mechanism and durability. Tatem 2020 pilot showed real pain reduction in hypogonadal middle-aged men. Mechanism plausibly via type III collagen synthesis upregulation + AR signaling in joint tissue. But this is hypogonadal cohort — extrapolation to young eugonadal users with peak T is unsupported and likely overstated.

  6. The "lean mass" reputation vs. controlled-trial findings. Prokopidis 2026 +1.59 kg LST is real but smaller than community-reported gains. Difference is partly placebo correction, partly study-population (often non-athletic, often on caloric restriction), partly the difference between supraphysiologic bodybuilding doses vs. clinical-trial doses.

  7. For the user specifically. Verdict is robust. Only post-30 + post-fertility-checkpoint + documented refractory joint pain in a non-tested category would re-open the question — none of which apply.

  8. Detection-window implications for amateur sport. The 12-18 month urine window via 19-norandrosterone metabolite is poorly understood by amateur athletes. A single 200 mg ND dose can produce positive WADA tests 9 months later (Forsdahl 2016). For any user considering competing in a sanctioned event within 18-24 months, ND is a hard-skip on detection window alone.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: SKIP-AT-20 (HIGH confidence) for this user-archetype. Rationale converges across HPG/fertility (deepest-in-class suppression at 20yo with still-maturing axis; recovery 6-18+ months; permanent dysfunction documented), sport regulation (WADA S1.1a + 12-18mo urine detection precludes any sanctioned competition), sexual function (signature PR-mediated "Deca dick" mechanism via prolactin/dopamine — opposite of brain-priority architecture), brain-priority (PR-mediated dopamine suppression, flat-affect potential), and alternative-availability (BPC-157 + collagen + load management cover the joint-trophic claim with no HPG/sexual/sport cost). HIGH (not MEDIUM) confidence because every axis converges. OPTIONAL-ADD for 30-50 hypogonadal men with refractory joint pain on TRT base with monitoring + cabergoline. NOT-INDICATED for clinical TRT, recovery-focused use in young eugonadal men, or aesthetic/mass goals at 20. PRIMARY-PICK historically for renal anemia (now superseded by rhEPO) and AIDS-wasting (now superseded).
▸ Open questions / gaps Open
  1. Modern A-tier RCTs in healthy adult athletes. Don't exist. The class never went through human-clinical-trial pathways for non-medical use. All athletic-performance evidence is observational, uncontrolled, or pilot.
  2. "Deca dick" prevention efficacy. Cabergoline is the standard adjunct but its prevention rate (vs. treatment of established symptoms) is not formally quantified. Some users develop ED despite prophylactic cabergoline.
  3. Functional strength gap (Prokopidis 2026 negative finding). Why does +1.59 kg LST fail to translate to handgrip strength? Possibilities: study population effect, dose differences vs. bodybuilding practice, the relevant strength gains are domain-specific (training-context-dependent), or the "lean mass" gain includes water/glycogen rather than contractile fiber.
  4. Mechanism of joint-pain relief. Type III collagen synthesis + AR-mediated joint tissue trophism is the leading hypothesis but not directly demonstrated in controlled human imaging studies.
  5. Long-term cardiovascular reversibility. AAS-induced LV hypertrophy and lipid changes — full reversibility on discontinuation is not consistently demonstrated. Nandrolone-specific contribution within stacks is impossible to isolate.
  6. The "smoother NPP" claim. Whether NPP genuinely produces less prolactin signal vs. Deca, controlling for total AUC, or whether this is reporting artifact, is unresolved.
  7. For this user specifically. Verdict is robust. Re-open trigger conditions: post-30 age, completed fertility checkpoint, documented hypogonadism with refractory joint pain, exit from any tested-sport category. None apply.

References

Tatem AJ, Holland LC, Kovac JR, Beilan JA, Lipshultz LI (2020) — Nandrolone decanoate relieves joint pain in hypogonadal men: prospective pilot study and review (Translational Andrology and Urology; PMC7108994; PMID 32257859)

pmc.ncbi.nlm.nih.gov · 2020

joint-pain pilot, 52% pain reduction in responders

View Study

Prokopidis K et al. 2026 — Effects of Nandrolone Decanoate on Muscle Strength, Body Composition and Bone Density: Systematic Review and Meta-Analysis (J Cachexia Sarcopenia Muscle, April 2026)

onlinelibrary.wiley.com · 2026

most current 20-RCT meta showing +1.59 kg LST, no handgrip improvement, inconsistent BMD

View Study

Storer TW, Woodhouse LJ, Sattler F, ... Bhasin S et al. 2005 — Nandrolone decanoate in HIV-infected men with weight loss (PMID 15914526)

pubmed.ncbi.nlm.nih.gov · 2005

A-tier RCT, AIDS-wasting indication

View Study

Frisoli A Jr, Chaves PH, Pinheiro MM, Szejnfeld VL 2005 — Effect of nandrolone decanoate on bone mineral density in elderly women with osteoporosis (J Gerontol A Biol Sci Med Sci 60:648-653; PMID 15972619)

pubmed.ncbi.nlm.nih.gov · 2005

A-tier BMD RCT

View Study

Sattler FR et al. 2005 — Nandrolone decanoate in HIV-infected women with weight loss (PMID 15767536)

pubmed.ncbi.nlm.nih.gov · 2005

multicenter RCT, female AIDS-wasting cohort

View Study

Nandrolone — Wikipedia

en.wikipedia.org

general background, mechanism, regulatory status

View Source

Nandrolone decanoate — Wikipedia

en.wikipedia.org

long-ester variant, FDA history

View Source

Nandrolone phenylpropionate — Wikipedia

en.wikipedia.org

short-ester variant

View Source

5α-Dihydronandrolone — Wikipedia

en.wikipedia.org

finasteride paradox mechanism

View Source

Pan MM, Kovac JR (2016) — Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness (Translational Andrology and Urology 5:213-219)

tau.amegroups.org · 2016

narrative review of off-label male-health uses

View Source

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…